A carregar...
Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives
Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. Nivolumab, a fully human IgG4 anti-PD-1 antibody,...
Na minha lista:
| Publicado no: | J Kidney Cancer VHL |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Codon Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5806048/ https://ncbi.nlm.nih.gov/pubmed/29468108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2018.102 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|